Allarta Life Science moves Canadian-developed Type 1 Diabetes Cell Therapy Closer to the Clinic

Allarta Life Science has received an award from Breakthrough T1D, the leading type 1 diabetes (T1D) research and advocacy organization, for the next stage of development needed to bring Allarta’s immune-protective LifeSpheres™ hydrogel technology to clinical trials. Allarta® technology aims to make cell therapy more accessible to people living with T1D by protecting transplanted insulin-producing cells without the need for lifelong immune-suppressing drugs.

Dr. Harald Stover, Allarta’s CEO and a professor of chemistry at McMaster University for more than 30 years, co-founded the company in 2019 with Maria Antonakos, Chief Operating Officer, to advance the technology pioneered in the Stover lab. The announcement opened McMaster University’s Innovation Showcase at McMaster Innovation Park, where Allarta is headquartered.

Next
Next

Help Ontario’s Biomanufacturing Workforce use AI with Judgement